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Abstract
Background: Despite effective antiretroviral therapy (ART), HIV-infected patients exhibit systemic inflammation, early
onset of age-related diseases, and features of immunosenescence. The role of inflammation in the development of
age-related diseases is widely recognized. However, the role of immunosenescence is not well established. Studying
immunosenescence in HIV-infection could give insight into its role in ageing processes. In this cross-sectional study,
we aimed to investigate whether ART-treated HIV-infected patients exhibit immunosenescence; and whether
immunosenescence is associated with age-related processes of inflammation, metabolism, adipose tissue, and
muscle. T cell immunosenescence and exhaustion were assessed by flow cytometry analysis of CD8+ cells from 43
ART-treated HIV-infected patients (HIV+) and ten Controls using markers of differentiation: CD27/CD28; maturation:
CD27/CD45RA; senescence: killer cell lectin-like receptor G1 (KLRG1); and exhaustion: programmed death-1 (PD-1).
Relationships between CD8+ T cell immunosenescence, exhaustion, and age-related processes were assessed using
linear regressions.
Results: HIV-infection was strongly associated with more highly differentiated and mature CD8+ T cell
phenotypes. PD-1 and KLRG1 expression did not differ between HIV+ and Controls, but depended on
differentiation and maturation stages of the cells. CD8+ T cell maturation was associated with age. KLRG1
expression was associated with age, metabolic syndrome, visceral adipose tissue, and high muscle mass.
PD-1 expression was not associated with age-related parameters.
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Conclusions: HIV-infection strongly affected CD8+ T cell differentiation and maturation, whereas age-related
processes were only weakly associated with immune parameters. Our findings suggest that, in contrast to
inflammation, immunosenescence appears to be highly dependent on HIV-infection and is only to a small
extent associated with age-related parameters in well-treated HIV-infection.
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Background
The world’s population is ageing rapidly. The population
of individuals aged 60 or over is the fastest growing, and
it is estimated to represent over 20 % of the world’s
population by 2050 [1]. As a result, the prevalence of
age-related diseases–such as cardiovascular diseases,
metabolic syndrome and diabetes, loss of muscle mass,
and cancer–is increasing. It is now evident that ageing
is associated with a state of chronic low-grade inflam-
mation known as “inflammaging”, and that most age-
related diseases are–in part–caused by inflammaging.
Inflammaging is characterized by elevated levels of
pro-inflammatory biomarkers such as interleukin-6
(IL-6), tumour necrosis factor alpha, and C-reactive
protein. However, it is not well known what causes the
increased inflammation [2, 3].
As immune cells are major producers of inflammatory
proteins, inflammaging could originate from the changes
that occur to immune cells during ageing, termed
immunosenescence [4]. Immunosenescence is character-
ized by decreased output of naïve T cells following
thymic involution, and accumulation of highly differenti-
ated memory CD8+ T cells as a result of repeated
antigenic stimulation and chronic viral infections such
as cytomegalovirus (CMV)-infection [5]. This results in
an inversion of the CD4:CD8 T cell ratio [5, 6]. The
highly differentiated T cells are senescent in that they
lose proliferative capacity, rendering them inefficient
against pathogens. However, they are able to produce
elevated amounts of pro-inflammatory cytokines [7–9].
Antiretroviral therapy (ART)-treated HIV-infected
patients are characterised by earlier onset of age-
associated diseases like cardiovascular diseases; features
of immunosenescence; inflammaging; and loss of T cell
effector functions, referred to as T cell exhaustion
[10–14]. Moreover, ART is associated with develop-
ment of lipodystrophy, a syndrome of adipose tissue
redistribution characterized by loss of subcutaneous
adipose tissue and gain of visceral adipose tissue
(VAT), and which resembles the changes in body
composition that occur with age [15, 16].
While immunosenescence is well-documented with
age, and is increasingly reported in treated HIV-
infection, it is not known whether these immunological
changes are involved in age-associated disease processes.
Studying the associations between immunosenescence
and clinical age-related processes in HIV-infected
patients could therefore yield insight into the role of
immunosenescence in disease development. In this
study we therefore wanted to investigate whether
ART-treated HIV-infected patients exhibit immunose-
nescence; and whether this immunosenescence is
associated with age-related processes of inflammation,
metabolism, adipose tissue, and muscle.
Methods
Study design and participants
Between November 2010 and October 2012, 75 partici-
pants were included in this cross-sectional study: 60
patients with HIV-infection (HIV+) and 15 healthy men of
similar age (Controls). HIV+ were recruited from the
Department of Infectious Diseases, and Controls were
recruited by advertisement at Copenhagen University
Hospital, Hvidovre, Denmark. Inclusion criteria were:
male sex; white ethnicity; > 18 years old; testing negative
for hepatitis B and C; no intravenous drug use; and no
current immunomodulating, lipid-lowering, anti-diabetic,
or endocrinologic treatment. HIV+ were also required to
have plasma HIV-RNA <400 copies/mL; ART for at least
12 months; and CD4+ T cell counts ≥200 cells/μL. The
relationships between inflammatory biomarkers, adipose
tissue distribution and low muscle mass in this cohort
have been investigated [17]. Moreover, microdialysis
results from 18 of the study participants have been
published in a methodological study [18]. The study was
approved by the local ethics committee of the Capital
Region of Denmark (H-4-2010-045), the Danish Data
protection agency (2010-41-4952), and was conducted in
accordance with the Declaration of Helsinki. All partici-
pants gave written informed consent.
Plasma inflammation markers and blood sample
measurements
Plasma levels of the inflammation markers soluble
urokinase plasminogen activator receptor (suPAR) and
IL-6 were measured by enzyme-linked immunosorbent
assays: suPARnostic (ViroGates A/S, Birkerød, Denmark)
and Quantikine HS-IL-6 (R&D Systems, Minneapolis,
MN). CD4+, CD8+ T cell counts, and HIV-RNA were
routine measurements by the Department of Clinical
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Biochemistry, Copenhagen University Hospital, Hvidovre,
Denmark. Peripheral blood mononuclear cells were isolated
by centrifugation using BD Vacutainer cell preparation
tubes (BD Biosciences, San Jose, CA) and cryopreserved.
Flow cytometric analysis of CD8+ T cells
Cryopreserved peripheral blood mononuclear cells from
all participants were thawed and washed in complete
RPMI 1640 media supplemented with GlutaMAX (Life
Technologies, Grand Island, NY), 10 % fetal bovine
serum, 100 U/mL penicillin, and 100 μg/mL strepto-
mycin. 1.5 million cells were resuspended in 100 μL PBS
and stained with the Zombie NIR Fixable Viability Kit
(BioLegend, San Diego, CA) for 30 min. Cells were
washed and resuspended in 10 % heat inactivated human
serum in PBS for 20 min for Fc receptor blocking. Cells
were incubated for 30 min with titrated anti-CD3-FITC,
anti-CD8-PerCp-Cy5.5, anti-CD27-APC, anti-CD28-PE-
Cy7 or anti-CD45RA-PE-Cy7 (BD Biosciences), and
anti-PD-1-PE or anti-KLRG1-PE (BioLegend) antibodies
and washed in FACS buffer (2 mM EDTA (Life Tech-
nologies) and 0.5 % bovine serum albumin (Miltenyi
Biotec, Cologne, Germany) in PBS). Matching isotype
and unstained controls were included for each partici-
pant. Compensations were generated for each fluoro-
chrome using CompBeads (Anti-Mouse Ig, κ) (BD
Biosciences). For each sample, 50 000 to 100 000 CD8+
events were recorded on a FACSCanto II flow cytometer
(BD Biosciences). HIV- and lipodystrophy-status of the
participants were concealed until after data analysis.
Data were analysed using Cytobank [19].
CD8+ T cells could be subtyped into four maturation
subsets based on CD27 and CD45RA expression: naïve
(TN: CD27
+CD45RA+); central memory (TCM: CD27
+CD45RA−); effector memory (TEM: CD27
−CD45RA−);
or effector memory re-expressing CD45RA (TEMRA:
CD27−CD45RA+) [20, 21]. By evaluating the expression
of CD27 and CD28, CD8+ T cells could also be subtyped
into four differentiation subsets: early differentiated
(TED: CD27
+CD28+); intermediate differentiated (TID:
CD27+CD28−); late differentiated (TLD: CD27
−CD28−);
or CD27−CD28+ [8]. The expression of the exhaustion
marker PD-1 and of the senescence marker KLRG1 was
evaluated in each of the maturation and differentiation
subsets and in the total CD8+ T cell population [22].
Assessment of body composition
Anthropometric measurements comprised body weight,
height, and waist and hip circumferences, measured as
in [15]. Abdominal VAT mass at the level of L4 was
derived from computed tomography scans (Somatom
Sensation 10, Siemens, Germany). Body composition
was determined by dual energy X-ray absorptiometry
(Norland XR-36, Gammatec A/S, Værløse, Denmark).
Fat mass index (FMI) was calculated as: total fat mass/
height2 (kg/m2). Leg lean mass index (lLMI) was calcu-
lated as: leg lean mass/height2 (kg/m2). Lean mass was
used as a surrogate marker for muscle mass as lean mass
is principally made of skeletal muscle. This is especially
true for lean mass in the extremities [23].
Assessment of metabolism
Fasting glucose levels were routine measurements by the
Department of Clinical Biochemistry. Fasting plasma
levels of insulin were measured using Immulite 2000
System (Siemens, NY, USA) and insulin resistance was
calculated using the homeostasis model assessment
(HOMA-IR) [24]. Metabolic syndrome was defined
according to the 2009 consensus definition for high risk
populations [25]. The assessment of metabolic syn-
drome was based on the presence of at least three of
the five following criteria: elevated waist circumference
(≥94 cm, as recommended for high risk populations);
elevated triglycerides (≥1.7 mmol/L); reduced HDL-C
(<1.0 mmol/L); elevated blood pressure (systolic ≥130
or diastolic ≥85 mm Hg, or anti-hypertensive treat-
ment); elevated fasting glucose (≥100 mg/dL).
Assessment of lipodystrophy
Lipodystrophy status and the type of lipodystrophy
were evaluated by clinical evaluation of the adipose
tissue distribution of several subcutaneous regions (i.e.
face, retroauricular and dorsocervical regions, upper arms,
thighs, buttocks, and abdomen) and of the visceral region,
as in [15]. HIV+ were characterized as lipodystrophic or
non-lipodystrophic. Patients with lipodystrophy were
further characterized as lipohypertrophic, lipoatrophic, or
having mixed type lipodystrophy.
Statistical analysis
Comparisons between HIV+ and Controls were per-
formed using unpaired Student’s t-test or Wilcoxon
two-sample test where appropriate. For categorical param-
eters, Chi-squared test or Fisher’s exact test were used. To
investigate the effect of HIV-infection on CD8+ T cell phe-
notypes, we used unpaired Student’s t-test or Wilcoxon
two-sample test and linear regression analyses. The associ-
ations between HIV-and ART-related variables and CD8+
T cell phenotypes were investigated in the HIV+ group
using multiple linear regression analyses adjusted for age.
The associations between age, inflammation, metabol-
ism, body composition, and CD8+ T cell phenotypes
were investigated in the HIV+ group using simple and
multiple linear regression analyses adjusted for age,
HIV-, ART-duration, and current ART. The TCM, TEM,
and TEMRA subsets were grouped into one Memory
group. Thus CD8+ T cell maturation was defined as
either an antigen-inexperienced naïve (TN) or an
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antigen-experienced Memory phenotype. CD8+ T cell
differentiation was defined as either an undiffe-
rentiated CD28+ phenotype composed of TED and
CD27−CD28+ cells, or a highly differentiated CD28−
phenotype composed of TID and TLD cells. The loss of
CD28 expression is considered to identify a group of
cells characterized by functional changes and replica-
tive senescence [9]. By grouping the individual subsets
according to relevant biological and functional charac-
teristics, we could reduce the number of analyses and
simplify the interpretation. Nonetheless, data on the
individual subsets are available as Additional files. Due
to the compositional nature of the data, only the
estimates of the Memory and CD28− cells are pre-
sented in analyses for group sizes. The estimates for
TN cells are the opposite of the estimates for Memory
cells since their proportions add up to 100 %, and the
same is true for CD28+ and CD28− cells. If the resid-
uals were not normally distributed, the parameter was
log-transformed to fulfil model requirements using
log2(x). Beta estimates (β) for log-transformed param-
eters were back transformed using (2β -1) × 100, and
thereby shown as percent change in outcome per unit
increase of the covariate.
Statistical significance was defined as a P-value < 0.05.
Analyses were performed using Statistical Analysis
Systems (SAS) version 9.4 (SAS Institute, Cary, NC,
USA). Graphs were made with GraphPad Prism version
6 (GraphPad Software, San Diego, CA, USA).
Results
Viable PBMCs were available from 53 of the 75 partici-
pants, and only these participants were included in the
study (Fig. 1). Flow cytometry analysis of maturation and
differentiation markers, and PD-1, was done for all 53
participants, whereas KLRG1 analyses was done for only
39 participants since not enough cells were available for
all participants.
General characteristics of the study participants are
summarized in Table 1. HIV+ had significantly higher
CD8+ T cell numbers (P < 0.0001) and lower CD4:CD8
ratio (P < 0.0001) than Controls. Smoking prevalence
(P = 0.05), HOMA-IR index (P = 0.05), and suPAR levels
(P = 0.02) were significantly higher in HIV+ compared
to Controls. Age and body composition did not differ
between HIV+ and Controls.
CD8+ T cell compartment re-modulation in HIV-infection
Lipodystrophy was not associated with changes in CD8+
T cell phenotype (Additional file 1 and Additional file 2).
Therefore, patients with and without lipodystrophy were
grouped (HIV+) in further analyses. CD8+ T cell maturation
phenotypes: naïve (TN), central memory (TCM), effector
memory (TEM), or effector memory re-expressing CD45RA
(TEMRA), were determined based on CD27 and CD45RA
expression. HIV+ had significantly lower proportions of TN
cells (P < 0.001) and significantly higher proportions of TEM
cells (P = 0.002) than Controls (Fig. 2a). CD8+ T cell differ-
entiation phenotypes: early (TED), intermediate (TID), late
(TLD) differentiated, or CD27
−CD28+, were determined
based on CD27 and CD28 expression. HIV+ had sig-
nificantly lower proportions of TED cells (P < 0.001)
and significantly higher proportions of TLD cells (P < 0.001)
than Controls (Fig. 2b). We investigated whether these
changes were mediated by differences in age or age-related
processes using multiple regression analyses. The dif-
ferences in CD8+ T cell subset distribution between
HIV+ and Controls were primarily related to HIV or
ART. Adjusting for age, inflammation, metabolism, or
body composition, hardly affected the associations
between HIV-infection and CD8+ T cell maturation
and differentiation (Additional file 3).
Moreover, we investigated whether HIV-, ART-duration
or current ART was associated with differences in CD8+ T
cell subset distribution in HIV-infected patients using
linear regressions adjusted for age. Current use of protease
inhibitors was significantly associated with higher propor-
tions of TEM (P = 0.002) and TLD (P = 0.002), and lower
proportions of TN (P = 0.007) and TED (P = 0.04) CD8
+ T
cells. Current use of non-nucleoside reverse-transcriptase
inhibitors was associated with higher proportions of
TID (P = 0.01). HIV- (P = 0.36–0.99) or ART-duration
(P = 0.07–0.94) did not have an effect on CD8+ T cell
subset sizes.
PD-1 and KLRG1 expression in HIV-infection
CD8+ T cell senescence and exhaustion were assessed on
the basis of KLRG1 and PD-1 expression, respectively.
HIV-infection did not have a significant effect on PD-1
and KLRG1 expression, neither in the total CD8+ T cell
population or in the subsets (P = 0.06–0.94) (Fig. 3).
Instead, PD-1 and KLRG1 expression depended on the
maturation and differentiation stages of the cells. PD-1
expression was highest in intermediate subsets (Fig. 3a).
KLRG1 expression was highest in highly differentiated
subsets (Fig. 3b). Moreover, there was a significant associ-
ation between proportions of PD-1+ and KLRG1+ CD8+ T
cells across both groups, the proportion of KLRG1+CD8+
T cells was multiplied by 2.7 % for each 1 % increase in
the proportion of PD-1+CD8+ T cells (Estimate = 2.72 %;
P = 0.02, 95 % CI = 0.45–5.04). We did not find any associ-
ation between HIV-, ART- duration, or ART and changes
in KLRG1 or PD-1 expression (P = 0.06–0.89).
Associations between CD8+ T cell subsets, age, and
age-related parameters
The aim of the study was to investigate changes
within the CD8+ T cell compartment in well-treated
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HIV-infected patients, and further to investigate
whether these changes were associated with age-
related parameters. In contrast to the virus, which is
thought to affect subsets with specific effector func-
tions, we expected the ageing process to have a more
general effect on the CD8+ T cell population. Therefore,
we grouped TCM, TEM, and TEMRA subsets into one Mem-
ory group; TED and CD27
−CD28+ cells into one CD28+
group; and TID and TLD into one CD28
− group. When
grouping the subsets, HIV-infection remained associated
with lower proportions of TN and CD28
+, and higher pro-
portions of Memory (P = 0.0002) and CD28− (P = 0.0003)
CD8+ T cells. We investigated the associations between
CD8+ T cell distribution, age, and age-related parameters
in the HIV+ group in simple and adjusted analyses (Fig. 4).
Analyses for the individual subsets are available in
Additional file 4. HOMA-IR index was significantly
associated with higher proportions of Memory (Un-
adjusted P = 0.02, adjusted P = 0.03), mainly TEM cells
(Unadjusted P = 0.02, adjusted P = 0.003), and lower
proportions of TN cells (Unadjusted P = 0.02, ad-
justed P = 0.03) (Fig. 4 and Additional file 4). We
found no significant associations between memory or
CD28− CD8+ T cell group sizes with age, inflamma-
tion or VAT overall (Fig. 4). However, at the indi-
vidual subset level, IL-6 levels were associated with
changes in the proportions of TID, and VAT was
associated with lower proportions of TEMRA CD8
+ T cells
(Additional file 4).
Associations between PD-1 and KLRG1 expression, age
and age-related parameters
We found PD-1 and KLRG1 expression to vary accord-
ing to subset differentiation and maturation, but not to
HIV-infection (Fig. 3). Thus, we wanted to investigate
whether PD-1 and KLRG1 expression in total CD8+ T
cells were associated with age and age-related processes
in the HIV+ group in simple and adjusted regression
analyses. When grouping the subsets, HIV-infection
was not associated with changes in KLRG1 or PD-1
expression (P = 0.14–0.87). There were no associations
between KLRG1 or PD-1 expression in total CD8+ T
cells and age-related parameters (Fig. 5).
Within each CD8+ T cell subset, there were still large
variations in the number of KLRG1+ and PD-1+ cells.
We therefore also investigated whether age and age-
related processes were associated with PD-1 and
KLRG1 expression in specific CD8+ T cell groups: TN
and Memory, and CD28+ and CD28− cells. In partici-
pants with metabolic syndrome, the proportion of
KLRG1+CD28− cells increased by 14 % in unadjusted
analyses, and by 18 % in adjusted analyses (Unadjusted
P = 0.05, adjusted P = 0.04), compared to those without
metabolic syndrome (Table 2). lLMI was associated
Fig. 1 Flowchart of the study participants. Abbreviations: HIV+: HIV-infected patients, KLRG1: killer cell lectin-like receptor G1, Lipo: lipodystrophic,
Non-Lipo: non-lipodystrophic, PBMC: peripheral blood mononuclear cell, PD-1: programmed death-1
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with an increase in the proportions of KLRG1+TN cells
(P = 0.02). VAT was associated with an increase in the
expression of KLRG1 in CD28+ (Unadjusted P = 0.02,
adjusted P = 0.03) and CD28− cells (Adjusted P = 0.04).
Associations of KLRG1 expression and metabolic
syndrome, VAT and lLMI were also observed in the
individual subsets (Additional file 5).
We found no associations between PD-1 expres-
sion and age-related parameters (Additional file 6
and Additional file 7).
Discussion
We investigated whether CD8+ T cell maturation, differ-
entiation, senescence, and exhaustion differed between
well-treated HIV-infected patients and Controls; and
whether these immunological changes were associated
with age and age-related processes of inflammation,
metabolism, adipose tissue, or muscle. HIV+ had signifi-
cantly higher levels of CD8+ T cells with mature and
highly differentiated phenotypes, but not higher levels of
CD8+ T cells expressing KLRG1 or PD-1 compared to
Controls. Instead, KLRG1 and PD-1 expression were
highly dependent on CD8+ T cell maturation and
differentiation. In contrast, age-related processes were
only weakly and inconsistently associated with CD8+ T
cell phenotypes.
In agreement with previous studies, HIV-infection was
strongly associated with lower proportions of relatively
Table 1 General characteristics of the study participants
Controls HIV+
N = 10 N = 43
Median or n IQR or % Median or n IQR or %
Demography and lifestyle
Age (years) 48.1 41.9–62.3 49.8 43.3–55.2
Smoking 0 0 % 14* 32.6 %
Body composition
Lipodystrophy — — 14 32.6 %
BMI (kg/m2) 25.4 24.7–28.6 25.1 23.0–27.7
FMI (kg/m2) 5.2 4.6–7.5 4.6 3.4–6.4
VAT (cm2) 111.6 93.5–157.5 150.8 115.0–212.2
lLMI (kg/m2) 6.4 6.2–6.8 6.1 5.7–6.6
Metabolic parameters
HOMA-IR 0.5 0.5–1.3 1.2* 0.6–2.4
Metabolic syndrome 1 10 % 20 46.5 %
Biomarkers of inflammation
IL-6 (pg/mL) 1.1 0.7–2.4 1.6 1.1–2.6
suPAR (ng/mL) 1.8 1.5–2.1 2.2* 1.8–2.8
HIV- and immune-related parameters
HIV duration (years) — — 14 6.6–21.0
ART duration (years) — — 10.2 4.4–14.8
Current PI treatment — — 13 30.2 %
Current NRTI treatment — — 43 100 %
Current NNRTI treatment — — 28 65.1 %
Other current ART — — 4 9.30 %
HIV RNA≤20 copies/mL — — 39 90.7 %
CD4+ T cell count (cells/μL) 729 674–880 580 403–820
CD8+ T cell count (cells/μL) 373 281–440 828*** 618–1120
CD4:CD8 ratio 2.0 1.8–3.0 0.7*** 0.5–1.0
Continuous measures are listed as: median and interquartile range. Categorical variables are listed as: number of participants and percentage
Abbreviations: BMI body mass index, ART antiretroviral therapy, FMI fat mass index, HOMA-IR homeostatic model assessment of insulin resistance, IL-6 interleukin-6, IQR
interquartile range, lLMI leg lean mass index, NRTI nucleoside reverse-transcriptase inhibitors, NNRTI non-nucleoside reverse-transcriptase inhibitor, PI protease inhibitor,
suPAR soluble urokinase plasminogen activator receptor, VAT visceral adipose tissue
The bold values are statistically significant at *P < 0.05, **P < 0.01, ***P < 0.001
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undifferentiated and naïve CD8+ T cells, higher propor-
tions of highly differentiated and mature CD8+ T cells,
and an inverted CD4:CD8 T cell ratio (<1) [12, 26].
These features are characteristic of the immunosenes-
cence phenotype previously described in healthy
elderly individuals [4]. However, while HIV-infection
is characterized by increased proportions of inter-
mediate TEM CD8
+ T cells, ageing is characterized by
increased proportions of more highly differentiated
TEMRA CD8
+ T cells, often attributed to CMV infec-
tion [21, 26–28]. This indicates that there are subtle
differences in the way CD8+ T cell subsets are affected
by HIV-infection and age.
HIV+ patients did not normalize their CD8+ matur-
ation and differentiation pattern despite successful ART,
indicating that HIV viral load is not the only driver of
CD8+ T cell phenotypic abnormalities. Other explana-
tions include disturbed thymic function [29, 30], ongoing
replication in HIV-reservoirs [31], co-infections by other
chronic viruses, and bacterial translocation in the gut
[32]. The effect of HIV-infection on CD8+ T cell matur-
ation and differentiation did not appear to be mediated
by age-related processes, since the estimates for the
associations between HIV-infection and T cell pheno-
types were unchanged when adjusted.
Previous studies have investigated the association
between lymphocytes phenotypes and age-associated
clinical outcomes, but with varying results. Highly
differentiated CD28−CD8+ T cells were associated with
frailty in older women [33]. Others have found associ-
ations of CD8+ T cell differentiation and maturation
with obesity in children [34]. CD8+ T cell maturation
was associated with HOMA-IR index. However, we
found HIV-infection to be associated with both higher
proportions of memory CD8+ T cells, and with ele-
vated HOMA-IR index. Thus HIV-infection could be a
confounder of this association. We did not observe
robust associations between CD8+ T cell maturation
and differentiation and body composition. Our results
are in agreement with Erlandson et al. who reported
an association of low physical function with inflamma-
tion, but not with highly differentiated CD28− T cells,
in HIV-infected patients, [35]. Moreover, Wallet et al.
reported neither elevated inflammation nor higher
proportions of senescent CD57+ CD4+ and CD8+ T cells
to be associated with physical function in older
HIV-infected patients [36].
HIV-infection was not associated with higher PD-1 or
KLRG1 expression in CD8+ T cells. However, PD-1 and
KLRG1 expression depended on differentiation and
maturation stages of the cells. Consistent with previous
studies, PD-1 expression was highest in intermediately
differentiated and mature subsets, and KLRG1 expres-
sion was highest in highly differentiated and mature
subsets [37–39]. PD-1 expression has been reported to
be dependent on HIV viral load [39]. In our study, the
majority of HIV+ had undetectable viral loads, which
may explain why PD-1 expression was not increased in
these patients. It is unclear whether KLRG1 expression
is also dependent on the viral load, and this could not be
investigated in our study due to the low number of
patients with detectable viral loads. These observations
suggest that CD8+ T cells from treated HIV-infected
patients appear to be functional despite the skewed
differentiation and maturation. However, due to the
limited number of viable cells and FACS lasers, we could
not investigate the functionality directly by assessing
functional markers like CD56; the co-expression of PD-1
a b
Fig. 2 CD8+ T cell maturation and differentiation in HIV+ and in Controls. a Proportions of CD8+ T cells in each maturation subset: naïve (TN),
central memory (TCM), effector memory (TEM), or effector memory re-expressing CD45RA (TEMRA) b Proportions of CD8
+ T cells in each differentiation
subset: early differentiated (TED), intermediate differentiated (TID), late differentiated (TLD), or CD27
−CD28+. HIV+ (N = 43) and Controls (N = 10). Medians
are shown as horizontal bars. P-values were determined using unpaired Student’s t-test or Wilcoxon two-sample test
Tavenier et al. BMC Immunology  (2015) 16:72 Page 7 of 14
and KLRG1, and co-expression with other inhibitory
receptors like TIM-3. But we did find a positive associ-
ation between KLRG1 and PD-1 expression. Investigating
CD56 in the subsets could have yielded insight into the
functionality of CD8+ T cells by assessing cytotoxicity
[40]. Moreover, assessing TIM-3 expression as a marker of
a b
Fig. 3 CD8+ T cell exhaustion and senescence in HIV+ and in Controls. a Proportions of PD-1+ cells in total CD8+ T cells and in CD8+ T cell subsets in
HIV-infection and in Controls. HIV+ (N = 43) and Controls (N = 10). b Proportions of KLRG1+ cells in total CD8+ T cells and in CD8+ T cell
subsets in HIV+ and in Controls. HIV+ (N = 30) and Controls (N = 9). Medians are shown as horizontal bars. P-values were determined using
unpaired Student’s t-test or Wilcoxon two-sample test
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exhaustion could have yielded insight into the exhaus-
tion of CD8+ T cells with cytotoxic effects (CD56+) as
in Poonia et al. [40]. Co-expression of several inhibitory
receptors may be necessary to affect cellular functions,
and may be a prominent feature in chronic viral infec-
tions [41, 42]. However, the aim of this study was to
assess the effect of immunosenescence and exhaustion
in CD8+ T cells on age and age-related parameters,
rather than CD8+ T cell functions. We therefore inves-
tigated KLRG1 and PD-1, as these have been shown to
reflect CD8+ T cell senescence and exhaustion [8, 14].
KLRG1 expression in the subsets, but not in total
CD8+ T cells, was influenced to a minor degree by
age-related processes of metabolism, adipose tissue,
and muscle. VAT and metabolic syndrome were asso-
ciated with higher KLRG1 expression in CD28+ and
Fig. 4 Unadjusted and adjusted associations between Memory and CD28−CD8+ T cells and ageing parameters in HIV+. Age was adjusted for
HIV-, ART-duration, and current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were adjusted for age, HIV-, ART-duration, and
current ART. Estimates are shown as unit increase in the outcome per unit increase of the covariate. The dashed line marks an estimate change
of 0 units. *P < 0.05. Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IL-6: interleukin-6; lLMI: leg lean mass index;
suPAR: soluble urokinase plasminogen activator receptor; VAT: visceral adipose tissue
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CD28− cells. KLRG1 expression in TN cells was associ-
ated with high muscle mass. However, due to the wide
confidence intervals for the associations with meta-
bolic syndrome and lLMI, and to the small estimate of
the association with VAT, further investigations are
required to determine whether these associations are
true, or whether they are artefacts. PD-1 expression
was not influenced by age-related parameters. More-
over, we did not find obvious associations between
CD8+ T cell phenotypes and inflammation, suggesting
Fig. 5 Unadjusted and adjusted associations between KLRG1+ and PD-1+CD8+ T cells and ageing parameters in HIV+. Age was adjusted for
HIV-, ART-duration, and current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were adjusted for age, HIV-, ART-duration, and
current ART. Parameters were transformed using log2(x). Estimates and 95 % CI are back transformed using (2
β-1) × 100 and shown as percent
change in the outcome per unit increase of the covariate. The dashed line marks an estimate change of 0 %. Abbreviations: HOMA-IR:
homeostatic model assessment of insulin resistance; IL-6: interleukin-6; KLRG1: killer cell lectin-like receptor G1; lLMI: leg lean mass index;
PD-1: programmed death-1; suPAR: soluble urokinase plasminogen activator receptor; VAT: visceral adipose tissue
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that highly differentiated, mature, senescent, or exhausted
CD8+ T cells may not be major contributors to systemic
IL-6 and suPAR levels.
In participants from this study, IL-6 and suPAR were
associated with FMI, VAT and low lLMI [17]. These
observations suggest that inflammation reflects age-
related processes of adipose tissue redistribution and
low muscle mass. In contrast, we did not find definite
associations of immunosenescence and T cell exhaustion
with age-related parameters or inflammation. This indi-
cates that CD8+ T cell immunosenescence and exhaustion
may not play major roles in inflammaging and age-related
processes in HIV-infected patients.
This study has some limitations. Its cross-sectional
nature does not allow for causal interpretation of the
associations. Since only ART-treated patients were in-
cluded, we could not determine whether our findings
were a result of HIV-infection, or ART, or a combin-
ation. Moreover, due to difficulties in including treat-
ment naïve patients, we were not able to include elite
controllers for comparison. By restricting the inclusion
criteria to men we aimed to limit variation in the
immune and inflammatory variables due to menopause
and menstrual cycle-related hormonal fluctuations [43].
Therefore, our findings are only representative for
men. The lack of data on CMV-seropositivity of the
participants may also be a limitation to the interpretation
of the results. CMV seroprevalence is higher in HIV-
infection (>75 %) than in the general population
(40–50 %) [44]. Thus, CMV-seropositivity could also
contribute to the skewed distribution of CD8+ T cells we
observed in HIV+. Another limitation to the study is the
likelihood of type I error due to multiple testing. We lim-
ited the number of analyses by grouping the CD8+ T cell
subsets into larger groups based on relevant biological and
functional features. Moreover, we based the interpretation
of our data on other findings, and did not make definite
conclusions from our findings that did not reach high
statistical significance. The study population was rela-
tively small due to a number of non-viable samples.
We therefore did not have sufficient power to assess
ageing parameters in the healthy Controls.
Conclusions
We showed that despite effective treatment, HIV-
infection is associated with a skewed distribution of
CD8+ T cells towards more differentiated and mature
phenotypes, suggestive of accelerated immune age-
ing. However, HIV-infection was not associated with
higher KLRG1 or PD-1 expression on CD8+ T cells.
Instead, the pattern of KLRG1 and PD-1 expression
followed subset distribution–and to a minor degree,
age. We did not find obvious relationships between
CD8+ T cell phenotypes and age-related processes of
Table 2 Unadjusted and adjusted associations between KLRG1+CD8+ T cell groups and ageing parameters in HIV+
Maturation - CD27/CD45RA Differentiation - CD27/CD28
% KLRG1+ TN
a % KLRG1+ Memorya % KLRG1+CD28+a % KLRG1+CD28−
Estimate 95 % CI Estimate 95 % CI Estimate 95 % CI Estimate 95 % CI
Age (per year extra) −0.84 −4.32 – 2.77 1.12 −2.19 – 4.53 1.54 −1.73 – 4.93 0.05 −0.81 – 0.92
−0.16 −4.22 – 4.07 0.32 −3.53 – 4.32 0.49 −3.16 – 4.28 −0.24 −1.24 – 0.76
IL-6 (per extra pg/mL) −0.24 −17.69 – 20.92 −8.07 −22.94 – 9.68 3.27 −13.80 – 23.71 −0.84 −5.53 – 3.85
−2.98 −21.71 – 20.23 −7.08 −23.90 – 13.47 9.10 −9.84 – 32.03 0.11 −5.16 – 5.38
suPAR (per extra ng/mL) −13.66 −40.90 – 26.14 −21.72 −44.54 – 10.50 −18.83 −42.12 – 13.82 −5.62 −14.38 – 3.14
−15.63 −43.65 – 26.30 −20.25 −45.09 – 15.84 −17.17 −41.55 – 17.38 −4.90 −14.36 – 4.56
HOMA-IR (per extra 1-unit) 16.39 −17.36 – 63.93 18.91 −13.42 – 63.30 27.27 −6.34 – 72.93 6.02 −1.96 – 14.01
35.74 −9.23 – 103.01 22.91 −16.71 – 81.38 27.45 −10.90 – 82.29 6.98 −2.65 – 16.16
Metabolic syndrome
(vs. no metabolic syndrome)
23.25 −34.76 – 132.83 46.43 −17.97 – 161.42 70.88 −1.41 – 196.17 14.31* 0.10 – 28.53
48.94 −29.02 – 212.55 41.31 −29.88 – 184.78 61.77 −15.73 – 210.55 17.59* 0.73 – 34.45
VAT (per extra cm2) −0.10 −0.55 – 0.35 0.28 −0.12 – 0.70 0.45* 0.06 – 0.84 0.10 −0.00 – 0.20
0.14 −0.54 – 0.82 0.28 −0.34 – 0.90 0.62* 0.07 – 1.16 0.16* 0.01 – 0.31
lLMI (per extra kg/m2) 66.47* 10.22 – 151.43 36.88 −5.52 – 98.30 22.54 −20.06 – 87.86 7.92 −2.88 – 18.71
59.19 −0.55 – 154.80 45.52 −1.35 – 114.65 33.83 −13.85 – 107.92 10.09 −1.22 – 21.39
Adjusted analyses are in grey. Age was adjusted for HIV-duration, ART-duration, and current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were
adjusted for age, HIV-duration, ART-duration, and current ART
Abbreviations: HOMA-IR homeostatic model assessment of insulin resistance, IL-6 interleukin-6, KLRG1 killer cell lectin-like receptor G1, lLMI leg lean mass index,
suPAR soluble urokinase plasminogen activator receptor, TN naïve T cell, VAT visceral adipose tissue
The bold values are statistically significant at *P < 0.05
aParameters were transformed using log2(x). Estimates and confidence intervals are back transformed using (2
β-1) × 100, and shown as percent change in the
outcome per unit increase of the covariate
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inflammation, metabolism, adipose tissue and muscle.
These findings suggest that in contrast to inflammation,
immunosenescence appears to be highly dependent on
HIV-infection and is only to a smaller extent associated
with age-related parameters in well-treated HIV-infected
patients. Moreover, CD8+ T cell differentiation, matur-
ation, senescence, or exhaustion did not appear to be
major causes of inflammaging in HIV-infected patients.
Additional files
Additional file 1: Figure S1. CD8+ T cell maturation and differentiation
in HIV+ with and without lipodystrophy, and Controls. (a) Proportions of
CD8+ T cells in each maturation subset: naïve (TN), central memory (TCM),
effector memory (TEM), or effector memory re-expressing CD45RA (TEMRA)
(b) Proportions of CD8+ T cells in each differentiation subset: early
differentiated (TED), intermediate differentiated (TID), late differentiated
(TLD), or CD27
−CD28+. HIV+ with lipodystrophy (Lipo) (N = 14), HIV+ without
lipodystrophy (Non-lipo) (N = 29), and Controls (N = 10). Medians are
shown as horizontal bars. P-values were determined using one-way
ANOVA. (PDF 64 kb)
Additional file 2: Figure S2. CD8+ T cell exhaustion and senescence
in HIV+ with and without lipodystrophy, and Controls. (a) Proportions
of PD-1+ cells in CD8+ T cell subsets and total CD8+ T cells in HIV+ with and
without lipodystrophy, and Controls. HIV+ with lipodystrophy (Lipo) (N = 14),
HIV+ without lipodystrophy (Non-lipo) (N = 29), and Controls (N = 10). (b)
Proportions of KLRG1+ cells in CD8+ T cell subsets and total CD8+ T cells in
HIV+ with and without lipodystrophy, and Controls. HIV+ with lipodystrophy
(Lipo) (N = 8), HIV+ without lipodystrophy (Non-lipo) (N = 22), and Controls
(N = 9). Medians are shown as horizontal bars. P-values were determined
using one-way ANOVA. (PDF 98 kb)
Additional file 3: Table S1. Linear regression analyses for the effect of
HIV-infection on CD8+ T cell maturation and differentiation. †Parameter
was transformed using log2(x). Estimates and confidence intervals are back
transformed using (2β-1) × 100, and shown as percent change in the
outcome per unit increase of the covariate. The bold values are statistically
significant at *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: HOMA-IR:
homeostatic model assessment of insulin resistance, IL-6: interleukin-6, lLMI:
leg lean mass index, suPAR: soluble urokinase plasminogen activator
receptor, TCM: central memory T cell, TED: early differentiated T cell, TEM:
effector memory T cell, TEMRA: effector memory T cell re-expressing CD45RA,
TID: intermediate differentiated T cell, TLD: late differentiated T cell, TN: naïve
T cell, VAT: visceral adipose tissue. (XLSX 14 kb)
Additional file 4: Table S2. Unadjusted and adjusted associations
between CD8+ T cell subset sizes and ageing parameters in HIV+. Adjusted
analyses are in grey. Age was adjusted for HIV-duration, ART-duration, and
current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were
adjusted for age, HIV-duration, ART-duration, and current ART. †Parameters
were transformed using log2(x). Estimates and confidence intervals are back
transformed using (2β-1) × 100, and shown as percent change in the outcome
per unit increase of the covariate. The bold values are statistically significant at
*P< 0.05, **P< 0.01, ***P< 0.001. Abbreviations: HOMA-IR: homeostatic model
assessment of insulin resistance, IL-6: interleukin-6, lLMI: leg lean mass index,
suPAR: soluble urokinase plasminogen activator receptor, TCM: central
memory T cell, TED: early differentiated T cell, TEM: effector memory
T cell, TEMRA: effector memory T cell re-expressing CD45RA, TID:
intermediate differentiated T cell, TLD: late differentiated T cell, TN:
naïve T cell, VAT: visceral adipose tissue. (XLSX 16 kb)
Additional file 5: Table S3. Unadjusted and adjusted associations
between KLRG1+CD8+ T cell subsets and ageing parameters in HIV+. Adjusted
analyses are in grey. Age was adjusted for HIV-duration, ART-duration, and
current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were
adjusted for age, HIV-duration, ART-duration, and current ART. †Parameters
were transformed using log2(x). Estimates and confidence intervals are back
transformed using (2β-1) × 100, and shown as percent change in the outcome
per unit increase of the covariate. The bold values are statistically significant at
*P< 0.05, **P< 0.01, ***P< 0.001. Abbreviations: HOMA-IR: homeostatic model
assessment of insulin resistance, IL-6: interleukin-6, KLRG1: killer cell lectin-like
receptor G1, lLMI: leg lean mass index, suPAR: soluble urokinase plasminogen
activator receptor, TCM: central memory T cell, TED: early differentiated T cell,
TEM: effector memory T cell, TEMRA: effector memory T cell re-expressing
CD45RA, TID: intermediate differentiated T cell, TLD: late differentiated T cell, TN:
naïve T cell, VAT: visceral adipose tissue. (XLSX 16 kb)
Additional file 6: Table S4. Unadjusted and adjusted associations
between PD-1+CD8+ T cell groups and ageing parameters in HIV+. Adjusted
analyses are in grey. Age was adjusted for HIV-duration, ART-duration, and
current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were
adjusted for age, HIV-duration, ART-duration, and current ART. †Parameters
were transformed using log2(x). Estimates and confidence intervals are back
transformed using (2β-1) × 100, and shown as percent change in the
outcome per unit increase of the covariate. Abbreviations: HOMA-IR:
homeostatic model assessment of insulin resistance, IL-6: interleukin-6,
PD-1: programmed death-1, lLMI: leg lean mass index, suPAR: soluble
urokinase plasminogen activator receptor, TCM: central memory T cell,
TED: early differentiated T cell, TEM: effector memory T cell, TEMRA: effector
memory T cell re-expressing CD45RA, TID: intermediate differentiated
T cell, TLD: late differentiated T cell, TN: naïve T cell, VAT: visceral
adipose tissue. (XLSX 15 kb)
Additional file 7: Table S5. Unadjusted and adjusted associations
between PD-1+CD8+ T cell subsets and ageing parameters in HIV+. Adjusted
analyses are in grey. Age was adjusted for HIV-duration, ART-duration, and
current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were
adjusted for age, HIV-duration, ART-duration, and current ART. †Parameters
were transformed using log2(x). Estimates and confidence intervals are back
transformed using (2β-1) × 100, and shown as percent change in the
outcome per unit increase of the covariate. Abbreviations: HOMA-IR:
homeostatic model assessment of insulin resistance, IL-6: interleukin-6,
PD-1: programmed death-1, lLMI: leg lean mass index, suPAR: soluble
urokinase plasminogen activator receptor, TCM: central memory T cell, TED: early
differentiated T cell, TEM: effector memory T cell, TEMRA: effector memory T cell
re-expressing CD45RA, TID: intermediate differentiated T cell, TLD: late
differentiated T cell, TN: naïve T cell, VAT: visceral adipose tissue. (XLSX 17 kb)
Abbreviations
ART: antiretroviral therapy; BMI: body mass index; CMV: cytomegalovirus;
FMI: fat mass index; HIV+: HIV-infected patient; HOMA-IR: homeostatic model
assessment of insulin resistance; IL-6: interleukin-6; KLRG1: killer cell lectin-like
receptor G1; lLMI: leg lean mass index; PD-1: programmed death-1;
suPAR: soluble urokinase plasminogen activator receptor; TCM: central
memory; TED: early differentiated; TEM: effector memory; TEMRA: effector
memory re-expressing CD45RA; TID: intermediate differentiated; TLD: late
differentiated; TN: naïve; VAT: visceral adipose tissue.
Competing interests
ViroGates A/S donated the suPARnostic® kits for suPAR measurements, but
did not have any influence on the design of the study. OA is inventor of the
patent on suPAR and risk. Hvidovre Hospital, Denmark, owns the patent
which is licensed to ViroGates A/S. JT, AL, THH, JHH, FKJ, and JP declare no
conflicts of interest.
Authors’ contributions
AL, JP, and OA designed the study. JT and AL carried out the laboratory
measurements. JHH participated in the coordination of the DXA scans. FKJ
evaluated the CT scans. JT, AL, THH, and JP participated in the statistical
analyses. JT wrote the manuscript with participation from AL, THH, JHH, JP,
and OA. All authors read and approved the final manuscript.
Acknowledgments
We thank all the individuals of the study for their participation.
We are also grateful to the staff at the Department of Infectious
diseases, Copenhagen University Hospital, Hvidovre, for assisting in
patient recruitment. We are very thankful to Michele Weber, Kristian
Zobbe, and Henrik Hedegaard Klausen for technical support and
assistance at examinations. This study was supported by Aase and
Ejnar Danielsens Fond and Arvid Nilssons Fond to AL.
Tavenier et al. BMC Immunology  (2015) 16:72 Page 12 of 14
Author details
1Optimed, Clinical Research Centre, Copenhagen University Hospital,
Hvidovre, Kettegård Alle 30, DK-2650 Hvidovre, Denmark. 2Department of
Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital,
Hvidovre, Kettegård Alle 30, DK-2650 Hvidovre, Denmark. 3Department of
Radiology, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30,
DK-2650 Hvidovre, Denmark. 4Section of Biostatistics, Department of Public
Health, Faculty of Health and Medical Sciences, University of Copenhagen,
Øster Farimagsgade 5, 1014 Copenhagen K., Denmark. 5Department of
Infectious Diseases, Copenhagen University Hospital, Hvidovre, Kettegård Alle
30, DK-2650 Hvidovre, Denmark.
Received: 6 August 2015 Accepted: 20 November 2015
References
1. Department of Economic and Social Affairs (Population Division), United
Nations. Volume I Comprehensive Tables. In: World Population Prospects :
The 2012 Revision. 2012. http://esa.un.org/unpd/wpp/publications/Files/
WPP2012_Volume-I_Comprehensive-Tables.pdf. Accessed 25 Nov 2015.
2. Singh T, Newman AB. Inflammatory markers in population studies of aging.
Ageing Res Rev. 2011;10:319–29.
3. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its
potential contribution to age-associated diseases. J Gerontol A Biol
Sci Med Sci. 2014;69 Suppl 1:S4–9.
4. Deeks SG. HIV Infection, Inflammation, Immunosenescence, and Aging.
Annu Rev Med. 2011;62:141–55.
5. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein
B. Gain and Loss of T Cell Subsets in Old Age—Age-Related Reshaping of
the T Cell Repertoire. J Clin Immunol. 2011;31:137–46.
6. Wikby A, Nilsson B-O, Forsey R, Thompson J, Strindhall J, Löfgren S, et al.
The immune risk phenotype is associated with IL-6 in the terminal decline
stage: Findings from the Swedish NONA immune longitudinal study of very
late life functioning. Mech Ageing Dev. 2006;127(8):695–704.
7. Akbar AN, Henson SM. Are senescence and exhaustion intertwined
or unrelated processes that compromise immunity?
Nat Rev Immunol. 2011;11:289–95.
8. Henson SM, Franzese O, Macaulay R, Libri V, Azevedo RI, Kiani-Alikhan S,
et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation
and proliferative dysfunction of highly differentiated CD8+ T cells.
Blood. 2009;113:6619–28.
9. Effros RB, Dagarag M, Spaulding C, Man J. The role of CD8+ T-cell replicative
senescence in human aging. Immunol Rev. 2005;205:147–57.
10. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a Model of Accelerated
or Accentuated Aging? J Gerontol A Biol Sci Med Sci. 2014;69(7):833–42.
11. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al.
Premature Age-Related Comorbidities Among HIV-Infected Persons
Compared With the General Population. Clin Infect Dis. 2011;53(11):1120–6.
12. Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, et al.
Composition and Function of T Cell Subpopulations Are Slow to
Change Despite Effective Antiretroviral Treatment of HIV Disease.
PLoS ONE. 2014;9:e85613.
13. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers
of Inflammation, Coagulation, and Renal Function Are Elevated in Adults
with HIV Infection. J Infect Dis. 2010;201:1788–95.
14. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al.
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to
reversible immune dysfunction. Nat Med. 2006;12:1198–202.
15. Andersen O, Haugaard SB, Andersen UB, Friis-Møller N, Storgaard H,
Vølund A, et al. Lipodystrophy in human immunodeficiency virus
patients impairs insulin action and induces defects in β-cell function.
Metabolism. 2003;52:1343–53.
16. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, et al.
Swiss HIV Cohort Study. Abnormalities of body fat distribution in HIV-infected
persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir
Immune Defic Syndr. 2002;31(1):50–5.
17. Langkilde A, Petersen J, Henriksen JH, Jensen FK, Gerstoft J, Eugen-Olsen J,
et al. Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated
with adiposity, lipodystrophy and low muscle mass in HIV-infected patients
and Controls. Immun Ageing. 2015;12:9.
18. Langkilde A, Andersen O, Henriksen JH, Langberg H, Petersen J, Eugen-Olsen J.
Assessment of in situ adipose tissue inflammation by microdialysis. Clin Physiol
Funct Imaging. 2015;35:110–9.
19. Kotecha N, Krutzik PO, Irish JM. Web-Based Analysis and Publication of Flow
Cytometry Experiments. Curr Protoc Cytom. 2010;Chapter 10:Unit10.17.
20. Henson SM, Akbar AN. KLRG1–more than a marker for T cell senescence.
Age. 2009;31:285–91.
21. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al.
Memory CD8+ T cells vary in differentiation phenotype in different
persistent virus infections. Nat Med. 2002;8:379–85.
22. Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, et al. CMV
and Immunosenescence: from basics to clinics. Immun Ageing. 2012;9:23.
23. Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human Body Composition:
Advances in Models and Methods. Annu Rev Nutr. 1997;17:527–58.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia. 1985;28:412–9.
25. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.
Harmonizing the Metabolic Syndrome A Joint Interim Statement of the
International Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and International
Association for the Study of Obesity. Circulation. 2009;120:1640–5.
26. Rosignoli G, Lim CH, Bower M, Gotch F, Imami N. Programmed death
(PD)-1 molecule and its ligand PD-L1 distribution among memory CD4
and CD8 T cell subsets in human immunodeficiency virus-1-infected
individuals. Clin Exp Immunol. 2009;157:90–7.
27. Derhovanessian E, Maier AB, Hähnel K, Beck R, de Craen AJM, Slagboom EP,
et al. Infection with cytomegalovirus but not herpes simplex virus induces
the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans.
J Gen Virol. 2011;92(12):2746–56.
28. Koch S, Larbi A, Derhovanessian E, Özcelik D, Naumova E, Pawelec G.
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets
in young and old people. Immun Ageing. 2008;5(1):6.
29. Ye P, Kirschner DE, Kourtis AP. The thymus during HIV disease: role in
pathogenesis and in immune recovery. Curr HIV Res. 2004;2:177–83.
30. Herasimtschuk AA, Hansen BR, Langkilde A, Moyle GJ, Andersen O, Imami N.
Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell
responses in patients on effective combination anti-retroviral therapy.
Clin Exp Immunol. 2013;173:444–53.
31. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al.
Identification of a Reservoir for HIV-1 in Patients on Highly Active
Antiretroviral Therapy. Science. 1997;278:1295–300.
32. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection:
causes and consequences. J Pathol. 2008;214:231–41.
33. Semba RD, Margolick JB, Leng S, Walston J, Ricks MO, Fried LP.
T cell subsets and mortality in older community-dwelling women.
Exp Gerontol. 2005;40:81–7.
34. Spielmann G, Johnston CA, O’Connor DP, Foreyt JP, Simpson RJ. Excess
body mass is associated with T cell differentiation indicative of immune
ageing in children. Clin Exp Immunol. 2014;176:246–54.
35. Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE,
et al. Association of Functional Impairment with Inflammation and Immune
Activation in HIV Type 1–Infected Adults Receiving Effective Antiretroviral
Therapy. J Infect Dis. 2013;208:249–59.
36. Wallet MA, Buford TW, Joseph AM, Sankuratri M, Leeuwenburgh C, Pahor M,
et al. Increased inflammation but similar physical composition and function
in older-aged, HIV-1 infected subjects. BMC Immunol. 2015;16:43.
37. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory Receptor
Expression Depends More Dominantly on Differentiation and Activation than
«Exhaustion» of Human CD8 T Cells. Front Immunol. 2013;4:455.
38. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, et al. PD-1
expression on human CD8 T cells depends on both state of differentiation
and activation status. AIDS. 2007;21:2005–13.
39. Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H,
et al. Programmed death-1 expression on CD4+ and CD8+ T cells in treated
and untreated HIV disease. AIDS. 2014;28:1749–58.
40. Poonia B, Pauza CD. Levels of CD56 + TIM-3- Effector CD8 T Cells Distinguish
HIV Natural Virus Suppressors from Patients Receiving Antiretroviral Therapy.
PLoS ONE. 2014;9:e88884.
Tavenier et al. BMC Immunology  (2015) 16:72 Page 13 of 14
41. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, Bordi R, et al. CD160 and
PD-1 Co-Expression on HIV-Specific CD8 T Cells Defines a Subset with
Advanced Dysfunction. PLoS Pathog. 2012;8:e1002840.
42. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, et al.
Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted
HCV-Specific CD8+ T Cells Is Linked to Antigen Recognition
and T Cell Differentiation. PLoS Pathog. 2010;6:e1000947.
43. Lee S, Kim J, Jang B, Hur S, Jung U, Kil K, et al. Fluctuation of peripheral
blood T, B, and NK cells during a menstrual cycle of normal healthy women.
J Immunol. 2010;181:756–62.
44. Lang DJ, Kovacs AA, Zaia JA, Doelkin G, Nilanhad JC, Aledort L, et al.
Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus
infections in relation to human immunodeficiency virus type 1 infection
in selected recipient populations. Transfusion Safety Study Group.
J Acquir Immune Defic Syndr. 1989;2:540–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tavenier et al. BMC Immunology  (2015) 16:72 Page 14 of 14
